Updates are available Correction dated 2020-07-22
Click to view Correction: https://doi.org/10.1007/s00330-020-07073-4
-
Authors
Chang, Gary H.
Felson, David T.
Qiu, Shangran
Guermazi, Ali
Capellini, Terence D.
Kolachalama, Vijaya B. https://orcid.org/0000-0002-5312-8644
-
Funding
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (1R01AR070139)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (1R01AR070139)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (1R01AR070139)
American Heart Association (17SDG33670323)
National Center for Advancing Translational Sciences (1UL1TR001430)
National Center for Advancing Translational Sciences (1UL1TR001430)
- License Information
-
More Information
Article History
Received: 20 November 2019
Revised: 2 January 2020
Accepted: 15 January 2020
First Online: 13 February 2020
Change Date: 22 July 2020
Change Type: Correction
Change Details: The original version of this article, published on 13 February 2020, unfortunately contained a mistake.
Compliance with ethical standards
:
: The scientific guarantor of this publication is Dr. David Felson (dfelson@bu.edu).
: Ali Guermazi is shareholder of BICL and consultant to Pfizer, AstraZeneca, TissueGene, Roche, Galapagos, and MerckSerono.
: No complex statistical methods were necessary for this paper. Additionally, Dr. Kolachalama has needed statistical expertise.
: Written informed consent was not required for this study because de-identified data is publicly available (Osteoarthritis Initiative: ). At the time of enrollment, informed consent and ethical committee approvals were obtained by the OAI investigators.
: Institutional Review Board approval was not required because the data was obtained from a public database (Osteoarthritis Initiative: ).
: The cohort has been reported in .
: • This is a case-control study.
